Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

ZONE vs NVAX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ZONE
CleanCore Solutions, Inc.

Industrial - Pollution & Treatment Controls

IndustrialsAMEX • US
Market Cap$3M
5Y Perf.-88.4%
NVAX
Novavax, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.50B
5Y Perf.+113.2%

ZONE vs NVAX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ZONE logoZONE
NVAX logoNVAX
IndustryIndustrial - Pollution & Treatment ControlsBiotechnology
Market Cap$3M$1.50B
Revenue (TTM)$3M$596M
Net Income (TTM)$-123M$-88M
Gross Margin58.5%84.6%
Operating Margin-9.8%-11.2%
Forward P/E3.6x
Total Debt$5M$249M
Cash & Equiv.$1M$241M

ZONE vs NVAXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ZONE
NVAX
StockApr 24May 26Return
CleanCore Solutions… (ZONE)10011.6-88.4%
Novavax, Inc. (NVAX)100213.2+113.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: ZONE vs NVAX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: NVAX leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ZONE
CleanCore Solutions, Inc.
The Long-Run Compounder

ZONE is the clearest fit if your priority is long-term compounding.

  • -89.7% 10Y total return vs NVAX's -90.4%
Best for: long-term compounding
NVAX
Novavax, Inc.
The Income Pick

NVAX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 2.11
  • Rev growth 64.7%, EPS growth 306.5%, 3Y rev CAGR -11.1%
  • Lower volatility, beta 2.11, current ratio 2.13x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthNVAX logoNVAX64.7% revenue growth vs ZONE's 29.2%
Quality / MarginsNVAX logoNVAX-14.7% margin vs ZONE's -35.8%
Stability / SafetyNVAX logoNVAXBeta 2.11 vs ZONE's 2.27
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)NVAX logoNVAX+55.1% vs ZONE's -77.4%
Efficiency (ROA)NVAX logoNVAX-7.4% ROA vs ZONE's -121.3%

ZONE vs NVAX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ZONECleanCore Solutions, Inc.
FY 2024
Other Member
100.0%$46,270
NVAXNovavax, Inc.
FY 2025
Product
50.0%$685M
Nuvaxovid Sales
45.6%$625M
Supply Sales
4.4%$60M

ZONE vs NVAX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLNVAXLAGGINGZONE

Income & Cash Flow (Last 12 Months)

NVAX leads this category, winning 5 of 6 comparable metrics.

NVAX is the larger business by revenue, generating $596M annually — 174.2x ZONE's $3M. NVAX is the more profitable business, keeping -14.7% of every revenue dollar as net income compared to ZONE's -35.8%. On growth, ZONE holds the edge at +3.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricZONE logoZONECleanCore Solutio…NVAX logoNVAXNovavax, Inc.
RevenueTrailing 12 months$3M$596M
EBITDAEarnings before interest/tax-$33M-$47M
Net IncomeAfter-tax profit-$123M-$88M
Free Cash FlowCash after capex-$8M-$96M
Gross MarginGross profit ÷ Revenue+58.5%+84.6%
Operating MarginEBIT ÷ Revenue-9.8%-11.2%
Net MarginNet income ÷ Revenue-35.8%-14.7%
FCF MarginFCF ÷ Revenue-2.3%-16.1%
Rev. Growth (YoY)Latest quarter vs prior year+3.2%-79.1%
EPS Growth (YoY)Latest quarter vs prior year-3.3%-102.0%
NVAX leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — ZONE and NVAX each lead in 1 of 2 comparable metrics.
MetricZONE logoZONECleanCore Solutio…NVAX logoNVAXNovavax, Inc.
Market CapShares × price$3M$1.5B
Enterprise ValueMkt cap + debt − cash$7M$1.5B
Trailing P/EPrice ÷ TTM EPS-0.46x3.63x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple2.56x
Price / SalesMarket cap ÷ Revenue1.48x1.34x
Price / BookPrice ÷ Book value/share2.10x
Price / FCFMarket cap ÷ FCF
Evenly matched — ZONE and NVAX each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

NVAX leads this category, winning 4 of 6 comparable metrics.

On the Piotroski fundamental quality scale (0–9), NVAX scores 5/9 vs ZONE's 2/9, reflecting solid financial health.

MetricZONE logoZONECleanCore Solutio…NVAX logoNVAXNovavax, Inc.
ROE (TTM)Return on equity-130.7%
ROA (TTM)Return on assets-121.3%-7.4%
ROICReturn on invested capital-93.9%
ROCEReturn on capital employed-110.2%+100.4%
Piotroski ScoreFundamental quality 0–925
Debt / EquityFinancial leverage3.69x
Net DebtTotal debt minus cash$4M$8M
Cash & Equiv.Liquid assets$1M$241M
Total DebtShort + long-term debt$5M$249M
Interest CoverageEBIT ÷ Interest expense-37.28x-5.10x
NVAX leads this category, winning 4 of 6 comparable metrics.

Total Returns (Dividends Reinvested)

NVAX leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ZONE five years ago would be worth $1,029 today (with dividends reinvested), compared to $524 for NVAX. Over the past 12 months, NVAX leads with a +55.1% total return vs ZONE's -77.4%. The 3-year compound annual growth rate (CAGR) favors NVAX at 7.4% vs ZONE's -53.1% — a key indicator of consistent wealth creation.

MetricZONE logoZONECleanCore Solutio…NVAX logoNVAXNovavax, Inc.
YTD ReturnYear-to-date+14.3%+29.5%
1-Year ReturnPast 12 months-77.4%+55.1%
3-Year ReturnCumulative with dividends-89.7%+23.9%
5-Year ReturnCumulative with dividends-89.7%-94.8%
10-Year ReturnCumulative with dividends-89.7%-90.4%
CAGR (3Y)Annualised 3-year return-53.1%+7.4%
NVAX leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

NVAX leads this category, winning 2 of 2 comparable metrics.

NVAX is the less volatile stock with a 2.11 beta — it tends to amplify market swings less than ZONE's 2.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVAX currently trades 77.1% from its 52-week high vs ZONE's 4.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricZONE logoZONECleanCore Solutio…NVAX logoNVAXNovavax, Inc.
Beta (5Y)Sensitivity to S&P 5002.27x2.11x
52-Week HighHighest price in past year$7.82$11.97
52-Week LowLowest price in past year$0.22$5.80
% of 52W HighCurrent price vs 52-week peak+4.6%+77.1%
RSI (14)Momentum oscillator 0–10056.064.4
Avg Volume (50D)Average daily shares traded2.0M4.4M
NVAX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricZONE logoZONECleanCore Solutio…NVAX logoNVAXNovavax, Inc.
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$18.00
# AnalystsCovering analysts23
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.3%
Insufficient data to determine a leader in this category.
Key Takeaway

NVAX leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.

Best OverallNovavax, Inc. (NVAX)Leads 4 of 6 categories
Loading custom metrics...

ZONE vs NVAX: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is ZONE or NVAX a better buy right now?

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus 29. 2% for CleanCore Solutions, Inc. (ZONE). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate Novavax, Inc. (NVAX) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — ZONE or NVAX?

Over the past 5 years, CleanCore Solutions, Inc.

(ZONE) delivered a total return of -89. 7%, compared to -94. 8% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: ZONE returned -89. 7% versus NVAX's -90. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — ZONE or NVAX?

By beta (market sensitivity over 5 years), Novavax, Inc.

(NVAX) is the lower-risk stock at 2. 11β versus CleanCore Solutions, Inc. 's 2. 27β — meaning ZONE is approximately 8% more volatile than NVAX relative to the S&P 500.

04

Which is growing faster — ZONE or NVAX?

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus 29. 2% for CleanCore Solutions, Inc. (ZONE). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -172. 4% for CleanCore Solutions, Inc.. Over a 3-year CAGR, ZONE leads at -7. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — ZONE or NVAX?

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -325. 3% for CleanCore Solutions, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -308. 1% for ZONE. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — ZONE or NVAX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is ZONE or NVAX better for a retirement portfolio?

For long-horizon retirement investors, CleanCore Solutions, Inc.

(ZONE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Novavax, Inc. (NVAX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ZONE: -89. 7%, NVAX: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between ZONE and NVAX?

These companies operate in different sectors (ZONE (Industrials) and NVAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

ZONE

High-Growth Disruptor

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 157%
  • Gross Margin > 35%
Run This Screen
Stocks Like

NVAX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 50%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ZONE and NVAX on the metrics below

Revenue Growth>
%
(ZONE: 315.5% · NVAX: -79.1%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.